Hypochondroplasia is a cause of disproportionate short stature and characterized by minor clinical manifestations. The aim of this study was to evaluate the efficacy of long-term growth hormone (GH) therapy in hypochondroplastic cases with inadequate response to GH stimulation tests. In this study, six patients who had a height standard deviation score of -3.43 before the treatment and a mean age of 7.42 years and who had received GH treatment at a dose of 0.2 mg/kg/week for a mean period of 4.45 years were evaluated. A good response was found in the first year of treatment, but this increase was not found to be sufficient for the patients to achieve an adequate final height.
Meyer MF, Menken KU, Zimny S, Hellmich B, Schatz H. Pitfall in diagnosing growth hormone deficiency in a hypochondroplastic patient with a delayed puberty. Exp Clin Endocrinol Diabetes 2003;111:177- 181.
Glasgow JF, Nevin NC, Thomas PS. Hypochondroplasia. Arch Dis Child 1978;53:868-872.
Maroteaux P, Falzon P. Hypochondroplasie. Review of 80 cases. Arch Fr Pediatr 1988;45:105-109.
Rimoin DL, Cohn D, Krakow D, Wilcox W, Lachman RS, Alanay Y. The skeletal dysplasias: clinical-molecular correlations. Ann. N Y Acad Sci 2007;1117:302-309.
Hagenäs L, Hertel T. Skeletal Dysplasia, Growth Hormone Treatment and Body Proportion: Comparison with Other Syndromic and NonSyndromic Short Children. Horm Res 2003;60:65-70.
Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of The Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press, 1959.
Marshall WA, Tanner JM. Variation in the pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.
Marshall WA, Tanner JM. Variation in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23.
Massart F, Miccoli M, Baggiani A, Bertelloni S. Hight outcome of short children with hypochondroplasia after recombinant human growth hormone treatment: a meta-analysis. Pharmacogenomics 2015;16:1965-1973. Epub 2015 Nov 10
Bellus GA, McIntosh I, Smith EA, Aylsworh AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995;10:357-359.
Grigelioniene G, Eklöf O, Laurencikas E, Ollars B, Hertel NT, Dumanski JP, Hägenas L. Asn540Lys mutation in fibroblast growth factor 3 and phenotype in hypochondroplasia. Acta Paediatr 2000;89:1072-1076.
Rousseau F, Bonaventure J, Legeai-Mallet L, Schmidt H, Weissenbach J, Maroteaux P, Munnich A, Le Merrer M. Clinical and genetic heterogeneity of hypochondroplasia. J Med Genet 1996;33:749-752.
Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet 2007;370:162- 172.
Appan S, Laurent S, Chapman M, Hindmarsh PC, Brook CG. Growth and growth hormone therapy in hypochondroplasia. Acta Paediatr Scand 1990;79:796-803.
Ramaswami U, Hindmarsh PC, Brook CG. Growth hormone therapy in hypochondroplasia. Acta Paediatr Suppl 1999;88:116-117.
Pinto G, Cormier-Daire V, Le Merrer M, Samara-Boustani D, Baujat G, Fresneau L, Viaud M, Souberbielle JC, Pineau JC, Polak M. Efficacy and safety of growth hormone treatment in children with hypochondroplasia: comparison with an historical cohort. Horm Res Paediatr 2014;82:355-363. Epub 2014 Oct 15
Kanaka-Gantenbein C. Present status of the use of growth hormone in short children with bone diseases (diseases of the skeleton). J Pediatr Endocrinol Metab 2001;14:17-26.